Mir-150-5p distinguishes acute pulmonary embolism, predicts the occurrence of pulmonary arterial hypertension, and regulates ox-LDL-induced endothelial cell injury

Yue Wu, Xin Sun, Guangqiang Cui, Shu WangHereditas 2024 · DOI

This study identifies miR-150-5p as a highly effective biomarker for diagnosing acute pulmonary embolism (APE) and predicting the onset of pulmonary arterial hypertension (PAH). Beyond its diagnostic utility, the researchers demonstrate that overexpressing this microRNA protects vascular endothelial cells from oxidative stress and inflammation, suggesting a potential therapeutic pathway for mitigating lung injury.

TL;DR

Researchers have identified miR-150-5p as a potent circulating biomarker that distinguishes acute pulmonary embolism (APE) from deep vein thrombosis (DVT) with high accuracy (AUC = 0.912). Furthermore, the study reveals that miR-150-5p plays a functional role in protecting endothelial cells from injury induced by oxidized low-density lipoprotein (ox-LDL), offering both a diagnostic tool and a potential therapeutic target.

What Problem Does This Paper Address?

Acute pulmonary embolism (APE) is a life-threatening condition where a blood clot blocks a pulmonary artery. It is a major complication of venous thromboembolism (VTE). Currently, clinicians rely on imaging (which is expensive and sometimes inaccessible) or D-dimer tests (which often lack the specificity to distinguish APE from other conditions).

There is a critical need for stable, specific biomarkers that can not only diagnose APE but also predict complications like pulmonary arterial hypertension (PAH)—a condition where high blood pressure in the lung arteries leads to right-heart failure. This paper investigates whether specific microRNAs (miRNAs), which are stable in the blood and easy to measure, can fill this diagnostic gap and play a role in the underlying disease mechanism.

Methods

The researchers employed a two-pronged approach: a clinical cohort study and an in vitro mechanistic study.

  1. Clinical Cohort: They enrolled 137 APE patients and 67 deep vein thrombosis (DVT) patients. They used RT-qPCR to measure miR-150-5p levels in plasma. Diagnostic performance was evaluated using Receiver Operating Characteristic (ROC) curves and Logistic Regression to identify risk factors for PAH.
  2. Cellular Model: To understand the biological role of the miRNA, they used Human Umbilical Vein Endothelial Cells (HUVECs). They induced cell injury using oxidized low-density lipoprotein (ox-LDL) to mimic the inflammatory and oxidative environment of APE.
  3. Functional Assays: They transfected cells with miR-150-5p "mimics" to see if increasing its levels could reverse damage. They measured cell proliferation (CCK-8), apoptosis (flow cytometry), pro-inflammatory cytokines (ELISA), and oxidative stress markers like Reactive Oxygen Species (ROS) and Superoxide Dismutase (SOD).

Datasets

The primary "dataset" consists of clinical data and plasma samples from 204 participants (137 APE, 67 DVT) recruited from Zibo Central Hospital between 2020 and 2022. The groups were matched for age, gender, and lipid profiles to minimize confounding variables.

Key Insights and Ideas

  • A Specific Signal in the Noise: While D-dimer is a standard test for clots, its specificity is notoriously low. This study found that miR-150-5p is significantly downregulated specifically in APE patients compared to DVT patients, providing a much clearer diagnostic signal.
  • Predicting PAH: One of the most significant findings is that miR-150-5p levels drop even further in APE patients who develop PAH. This suggests the miRNA could serve as an early warning system for patients at risk of severe hemodynamic complications.
  • From Marker to Mediator: The paper moves beyond simple correlation. By showing that miR-150-5p mimics can "rescue" HUVECs from ox-LDL-induced death and inflammation, the authors suggest that the loss of this miRNA isn't just a symptom of APE—it's likely part of the pathology that drives endothelial dysfunction.
  • Oxidative Stress Regulation: The miRNA appears to work by modulating the balance of oxidative stress, specifically by increasing SOD (an antioxidant enzyme) and decreasing MDA (a marker of lipid peroxidation).

Key Results

  • Diagnostic Accuracy: miR-150-5p distinguished APE from DVT with an Area Under the Curve (AUC) of 0.912, significantly outperforming the standard D-dimer test (AUC = 0.702) in this cohort.
  • PAH Prediction: For distinguishing APE patients with PAH from those without, the miRNA achieved an AUC of 0.831.
  • Risk Factor: Logistic regression identified reduced miR-150-5p as a significant risk factor for PAH (Odds Ratio = 0.385).
  • Cytoprotection: In cell models, overexpressing miR-150-5p significantly reduced the levels of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and suppressed apoptosis compared to injured control cells.

Limitations and Future Work

  • Single-Center Study: The clinical data comes from one hospital, which may introduce selection bias. Multi-center studies with more diverse populations are needed to validate these findings.
  • Lack of In Vivo Data: While the HUVEC model is a standard starting point, the protective effects of miR-150-5p need to be confirmed in animal models of APE to see if it can actually improve survival or lung function in a living system.
  • Mechanism Specificity: The study shows that miR-150-5p protects cells, but the exact molecular "targets" (the specific genes it silences to achieve this effect) remain to be identified. Future research should focus on the downstream signaling pathways regulated by this microRNA.

Summary updated

Abstract

Downregulated plasma miR-150-5p served as a diagnostic biomarker for APE and predicted the predisposition of PAH in APE patients. Overexpressing miR-150-5p could alleviate ox-LDL-induced endothelial cell injury in HUVECs.
BibTeX
@inproceedings{wu2024mir,
  author = {Yue Wu and Xin Sun and Guangqiang Cui and Shu Wang},
  title = {{Mir-150-5p distinguishes acute pulmonary embolism, predicts the occurrence of pulmonary arterial hypertension, and regulates ox-LDL-induced endothelial cell injury}},
  booktitle = {Hereditas},
  year = {2024},
  doi = {10.1186/s41065-024-00333-z},
}
Figure